| Popis: |
Eva M Donato,1 Miguel Fernández-Zarzoso,1 Jose Antonio Hueso,1 Javier de la Rubia1,2 1Hematology Service, University Hospital Doctor Peset, Valencia, Spain; 2Department of Internal Medicine, Universidad Católica de Valencia “San Vicente Mártir,” Valencia, Spain Abstract: Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date. Keywords: anaplastic large-cell lymphoma, anti-CD30 antibody, brentuximab vedotin, Hodgkin lymphoma |
